Dawson James Starts Arch Therapeutics (ARTH) at Buy, $3 PT

May 5, 2021 7:53 AM EDT
Get Alerts ARTH Hot Sheet
Price: $0.10 --0%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 4 | Down: 4 | New: 21
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Dawson James analyst Jason Kolbert initiates coverage on Arch Therapeutics (OTC: ARTH) with a Buy rating and a price target of $3.00.

The analyst commented, "Arch is developing an innovative platform of peptides that act as a barrier to seal and protect against infection as well as control bleeding, leaking, and injured tissues in a range of procedures. The initial product is based on the AC5, a self-assembling peptide technology platform, which rapidly generates nanofiber networks that control the movement of fluids and substances while enabling healing. The product is now approved in the U.S., and commercialization has begun. The E.U. is next. As resources allow, we expect to see indications expand and new products emerge from the pipeline."

For an analyst ratings summary and ratings history on Arch Therapeutics click here. For more ratings news on Arch Therapeutics click here.

Shares of Arch Therapeutics closed at $0.13 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Hot New Coverage, New Coverage